Table 3.
Suggested Treatment Regimens for Diabetes Mellitus in the Liver Allograft Recipient (From Bechetti et al [8]).
| Co-morbidity | First line | Second line |
|---|---|---|
| Atherosclerotic disease | GLP 1RA | SGLT2i |
| Heart failure | SGLT2i | GLP 1RA |
| Renal impairment | SGLT2i | GLP 1RA |
| Obesity | SGLT2i/GLP 1RA | DPP-4i |
| NAFLD | Pioglitazone | DPP-4i |
| Β-cell dysfunction | Pioglitazone DPP-4i | GLP 1RA, SGLT2i |
GLP 1RA: glucagon-like peptide-1 receptor agonists.
DPP-4i: inhibitors of dipeptidyl peptidase 4.
SGLT2i: sodium–glucose cotransporter 2 inhibitors.
NAFLD: non-alcoholic fatty liver disease.